Pregnancy
Conditions
Brief summary
A new technique based on the motile sperm organelle morphology examination (MSOME) at a magnification of at least ×6000 has been developed. The MSOME assesses the nucleus, for both shape and chromatin content, which is the most important sperm organelle in influencing intracytoplasmic sperm injection (ICSI) outcomes.
Detailed description
Sperm morphology has been described as one of the major determinants of male in vitro fertility. However, the standard morphology evaluation on random stained cells from the ejaculate is of limited value during ICSI. Current research is directed towards the dysmorphisms of the sperm head.A new technique based on the motile sperm organelle morphology examination (MSOME) at a magnification of at least ×6000 has been developed. The MSOME assesses the nucleus, for both shape and chromatin content, which is the most important sperm organelle in influencing ICSI outcomes. The goals for this study are to identify whether there is a connection between morphologic sperm normalcy under high magnification and (i) semen analysis according to the new World Health Organization (WHO) reference values and (ii) ICSI outcomes.
Interventions
The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form \> 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
Sponsors
Study design
Eligibility
Inclusion criteria
* Couples undergoing ICSI as result of male factor or tubal factor or unexplained infertility * Women with regular menstrual cycles of 25-35 days * Women with normal basal follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels * Women with body mass index (BMI) less than 30 kg/m2 * Women with both ovaries and intact uterus
Exclusion criteria
* Women with polycystic ovaries syndrome * Women with endometriosis * Women with gynaecological/medical disorders * Couples with any sexually transmitted disease * Women who had received any hormone therapy for less than 60 days preceding the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pregnancy rates | 1 month | Number of clinical pregnancy rate divided by the number of couples in which embryo transfer was performed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Implantation rates | 1 month | Number of gestational sacs divided by the number of transferred embryos. |
Countries
Brazil